In the last trading session, 7.09 million shares of the Novavax, Inc (NASDAQ:NVAX) were traded, and its beta was 2.04. Most recently the company’s share price was $8.94, and it changed around $0.64 or 7.71% from the last close, which brings the market valuation of the company to $1.54B. NVAX currently trades at a discount to its 52-week high of $23.86, offering almost -166.89% off that amount. The share price’s 52-week low was $3.53, which indicates that the current value has risen by an impressive 60.51% since then. We note from Novavax, Inc’s average daily trading volume that its 10-day average is 4.06 million shares, with the 3-month average coming to 6.09 million.

Novavax, Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 2 recommended NVAX as a Hold, whereas 2 deemed it a Buy, and 1 rated it as Underweight. Novavax, Inc is expected to report earnings per share of -0.65 for the current quarter.

Novavax, Inc (NASDAQ:NVAX) trade information

Instantly NVAX has showed a green trend with a performance of 7.71% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 9.55 on recent trading dayincreased the stock’s daily price by 6.39%. The company’s shares are currently up 86.25% year-to-date, but still up 2.52% over the last five days. On the other hand, Novavax, Inc (NASDAQ:NVAX) is -0.22% down in the 30-day period. We can see from the shorts that 41.51 million shares have been sold at a short interest cover period of 5.97 day(s).

The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 59.36% from its current value. Analyst projections state that NVAX is forecast to be at a low of $14 and a high of $25.

Novavax, Inc (NVAX) estimates and forecasts

Novavax, Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -50.80 percent over the past six months and at a 73.38% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be -30.46%, down from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 90.92M in revenue for the current quarter. 1 analysts expect Novavax, Inc to make 47.5M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 291.34M and 93.86M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -68.79%. Forecasts for the next quarter put sales growth at -49.39%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.55%. Novavax, Inc earnings are expected to increase by 73.63% in 2024, but the outlook is positive 37.90% per year for the next five years.

NVAX Dividends

Novavax, Inc’s next quarterly earnings report is expected to be released in January.

Novavax, Inc (NASDAQ:NVAX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 4.38% of Novavax, Inc shares, and 60.34% of them are in the hands of institutional investors. The stock currently has a share float of 63.10%. Novavax, Inc stock is held by 324.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 10.0599% of the shares, which is about 14.08 million shares worth $178.19 million.

BLACKROCK INC., with 8.4669% or 11.85 million shares worth $149.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.